Trial site
SFM Clinical Research LLC
Boca Raton, Florida 33487, United StatesNot linked to an institution yet
- 14running trials
- 2closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 25 trials
- Phase 1/21 trial
- Status
- Active, not recruiting7 trials
- Recruiting7 trials
- Completed1 trial
- Terminated1 trial
- Lead sponsor
- argenx3 trials
- Alector Inc.1 trial
- Cartesian Therapeutics1 trial
- Cerevance1 trial
- Cerevance Beta, Inc.1 trial
- and 9 more
Running trials
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
NCT07250750· Phase 1/2· ImmunAbs Inc.· Source
Contact: Gabrielle DeMaria
Recruiting
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
NCT07217587· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
NCT06298565· argenx· Source
Contact: Marc Feinberg, MD
Recruiting
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· Phase 2· Intra-Cellular Therapies, Inc.· Source
Active, not recruiting
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027· Phase 3· Cerevance· Source
Active, not recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279· Phase 3· argenx· Source
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source
Contact: Marc H Feinberg (principal investigator)
Recruiting
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NCT06414954· Phase 2· NMD Pharma A/S· Source
Contact: Gabrielle DeMaria
Active, not recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552· Phase 3· argenx· Source
Active, not recruiting
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717· Phase 3· Theravance Biopharma· Source
Active, not recruiting
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
NCT04146051· Phase 2· Cartesian Therapeutics· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error